Dr Busteed has more than 15 years experience in the life sciences sector, specialising in corporate and business development, strategic planning and operations. She joins Enigma from Focus Diagnostics, Inc., a US-based company providing products and services for the diagnosis of infectious diseases. At Focus Diagnostics, Dr Busteed was Vice President for Corporate Development with responsibility for a broad range of business development, licensing and M&A activities and a particular emphasis on acquisition of platforms and technology to fuel growth of the diagnostics products business.
From 2001 to 2004, Dr Busteed was Senior Director, Business Development and Strategic Planning at US company Celera Genomics Group (NYSE:CRA - News), a leader in the field of targeted medicine based on its genomics, proteomics and molecular diagnostics businesses.
Prior to this she spent seven years at management consulting firm McKinsey & Company in France and the UK where she gained broad experience in both strategic and operational consulting focusing on healthcare, chemicals and basic materials industries.
John McKinley, Chairman of Enigma Diagnostics, said: "I am extremely pleased that we have been able to attract Lynn to lead Enigma's executive team at this important phase of our development. Her experience is highly relevant to the company's product growth and to our broad US and European market focus. Lynn's appointment significantly strengthens the team that we have been building over the past six months and we warmly welcome her to Enigma."
Lynn Busteed added: "I have been strongly impressed with the high quality of Enigma's technology and the strength of the management team that has been assembled. I very much look forward to working with Enigma to realize its ambitious goals for the development and growth of products to target the global diagnostics markets for infectious diseases."
Notes to Editors:
About Enigma Diagnostics
Enigma Diagnostics Limited is a private UK based company developing the next generation of rapid diagnostic instrument platforms for the detection and identification of infectious organisms, such as bacteria and viruses, in clinical, environmental and biological samples.
Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based and point-of-care tests. The Company is targeting a number of multi-billion pound markets, core among which are the clinical, defence and homeland security, and veterinary markets. Enigma's commercialisation strategy is to maximise revenues from a continuous flow of market leading rapid diagnostic point-of-care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will build an in-house sales and marketing capability to direct distribution of its bespoke products and partner with market leaders where global penetration of markets is required.
Enigma has an exclusive licence from the Defence Science Technology Laboratory to a portfolio of patents which represent over 15 years of UK Ministry of Defence funded research. Enigma's own R&D activities have added additional patents and design rights based upon its proprietary technologies to generate a portfolio of over 35-plus worldwide patents and patent applications dedicated to real-time PCR and wider rapid technologies. All of these patents are granted in a range of core territories such as US, EU and Japan with more extensive filing and grants across a number of other key territories.
www.enigmadiagnostics.com
Contacts Enigma Diagnostics +44-(0)1980-590131 Deborah Cordingley, Corporate Communications deborah.cordingley@enigmadiagnostics.com Citigate Dewe Rogerson +44-(0)207-638 9571 Mark Swallow / David Dible / Valerie Auffray mark.swallow@citigatedr.co.uk
Source: Enigma Diagnostics
